CRISPR Therapeutics names A.J. Silver CFO, succeeding Raju Prasad

CRSP•2026-10-19

CRISPR Therapeutics appointed senior vice president of finance A.J. Silver as chief financial officer, effective October 19, 2026. Raju Prasad is leaving to pursue external opportunities.

1. CFO transition

CRISPR Therapeutics appointed A.J. Silver, its senior vice president of finance, as chief financial officer, effective October 19, 2026. Silver joined the company in October 2018 and had served as senior vice president of finance since January 2025. Outgoing CFO Raju Prasad is leaving to pursue external opportunities.

CRISPR Therapeutics names A.J. Silver CFO, succeeding Raju Prasad

1. CFO transition

Related News

Curanex Pharmaceuticals faces securities class actions over alleged IPO disclosure failures

CoinShares director Daniel Masters reports sale of $433,569.9448 in common shares

Stardust Power faces Nasdaq delisting over minimum bid price violation

3M expands strategic commercial partnership with Amazon

Albertsons awards director Harmit Singh 5,423 restricted stock units